Detailed financial statements for Dyadic International, Inc. (DYAI): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Analysis Summary
Dyadic International, Inc. reported revenue of $1.2M in the most recent fiscal year, growing at a 5-year CAGR of -5.1%.
Trailing-twelve-month margins: gross margin 30.4%, operating margin -213.6%, net margin -219.5%.
At the current price of $0.40, DYAI has negative trailing earnings (P/E not meaningful) and an ROE of -29.18%. Market capitalisation stands at $15M.
Balance sheet quality for DYAI: current ratio of 2.7, net cash position of $2.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $592886 | $758420 | $1.3M | $1.7M | $1.6M | $2.4M | $2.9M | $2.9M | $3.5M | $1.2M |
| Cost of Revenue | $516162 | $680197 | $1.0M | $1.5M | $1.4M | $1.9M | $2.1M | $2.0M | $1.2M | $2.3M |
| Gross Profit | $76724 | $78223 | $268173 | $221375 | $176990 | $459393 | $807110 | $922957 | $2.3M | -$1.1M |
| Research & Development | $885602 | $2.2M | $3.3M | $5.4M | $3.9M | $8.4M | $4.5M | $3.3M | $2.0M | $2.2M |
| Selling, General & Admin | $4.6M | $5.0M | $4.5M | $5.5M | $6.1M | $6.7M | $6.4M | $5.8M | $6.1M | $5.8M |
| Operating Expenses | $5.9M | $7.5M | $7.8M | $9.5M | $10.2M | $15.2M | $11.0M | $9.2M | $8.2M | $6.1M |
| Operating Income | -$6.0M | -$7.1M | -$7.6M | -$9.3M | -$10.0M | -$14.7M | -$10.2M | -$8.2M | -$5.9M | -$7.1M |
| EBITDA | 0 | -$2.2M | -$7.6M | 0 | -$10.0M | -$11.1M | -$10.1M | -$8.2M | -$5.4M | -$6.9M |
| Interest Expense | $909 | $566146 | $894532 | 0 | 0 | 0 | 0 | 0 | $427971 | $455897 |
| Pre-tax Income | -$3.4M | -$2.2M | -$6.7M | -$8.3M | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| Income Tax | $238073 | -$66694 | -$1.0M | $10306 | $31318 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.6M | -$2.1M | -$5.7M | -$8.3M | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| EPS | $-0.10 | $-0.07 | $-0.21 | $-0.31 | $-0.34 | $-0.47 | $-0.34 | $-0.24 | $-0.20 | $-0.23 |
| EPS (Diluted) | $-0.10 | $-0.07 | $-0.21 | $-0.31 | $-0.34 | $-0.47 | $-0.34 | $-0.24 | $-0.20 | $-0.23 |
| Shares Outstanding (Diluted) | $36.5M | $28.9M | $27.7M | $27.0M | $27.5M | $27.8M | $28.4M | $28.8M | $29.3M | $32.6M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.9M | $5.8M | $2.4M | $4.8M | $20.6M | $15.7M | $5.8M | $6.5M | $6.5M | $4.6M |
| Short-term Investments | $42.1M | $41.9M | $38.8M | $29.4M | $8.5M | $4.5M | $6.8M | $748290 | $2.8M | $2.7M |
| Receivables | $1.1M | $760870 | $1.1M | $1.1M | $294199 | $372206 | $330001 | $466159 | $237027 | $1.1M |
| Inventory | $7.4M | $1.0M | $253446 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $57.6M | $49.6M | $42.7M | $35.6M | $29.8M | $21.0M | $13.4M | $8.1M | $9.8M | $9.9M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $141439 | $92211 | $38535 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $58.7M | $50.7M | $43.3M | $37.5M | $30.1M | $21.3M | $13.7M | $8.2M | $9.9M | $9.9M |
| Accounts Payable | $279057 | $520261 | $309060 | $792995 | $1.0M | $1.5M | $1.3M | $656445 | $482320 | $852024 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.0M | $768895 | $849638 | $1.6M | $1.6M | $2.6M | $2.4M | $2.3M | $2.4M | $3.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.0M | $5.0M |
| Total Liabilities | $1.0M | $768895 | $849638 | $1.6M | $1.6M | $2.9M | $2.6M | $2.3M | $7.5M | $8.7M |
| Retained Earnings | -$25.2M | -$27.4M | -$33.0M | -$41.4M | -$50.7M | -$63.7M | -$73.5M | -$80.3M | -$86.1M | -$93.5M |
| Total Equity | $57.7M | $50.0M | $42.5M | $35.9M | $28.4M | $18.4M | $11.1M | $5.9M | $2.5M | $1.2M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $136929 | $5.1M | $5.1M |
| Net Debt | -$48.9M | -$47.7M | -$41.2M | -$34.2M | -$29.1M | -$20.3M | -$12.6M | -$7.1M | -$4.2M | -$2.3M |
| Working Capital | $56.6M | $48.8M | $41.9M | $34.1M | $28.2M | $18.5M | $11.0M | $5.8M | $7.4M | $6.2M |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$3.6M | -$2.1M | -$5.7M | -$8.3M | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| Depreciation & Amortization | 0 | 0 | $676644 | 0 | 0 | 0 | 0 | 0 | 0 | -$24169 |
| Stock-based Compensation | $624808 | $643430 | $467203 | 0 | $1.7M | $1.8M | $1.9M | $1.2M | $1.1M | $930183 |
| Change in Working Capital | -$2.7M | -$840779 | $119942 | $1.1M | $990075 | $1.2M | -$321169 | -$143209 | $754526 | $660795 |
| Operating Cash Flow | -$6.0M | -$2.6M | -$4.4M | -$5.8M | -$6.6M | -$11.3M | -$8.1M | -$6.7M | -$4.0M | -$5.7M |
| Capital Expenditure | 0 | 0 | 0 | $2 | $2 | 0 | 0 | 0 | -$4 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | -$13.3M | -$6.2M | -$2.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$6.0M | -$2.6M | -$4.4M | -$5.8M | -$6.6M | -$11.3M | -$8.1M | -$6.7M | -$4.0M | -$5.7M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +27.9% | +70.8% | +29.8% | -4.7% | +50.1% | +21.9% | -1.1% | +20.6% | -64.7% | |
| Net Income Growth (YoY) | +40.8% | -166.5% | -46.0% | -12.2% | -40.2% | +25.5% | +30.2% | +14.5% | -26.8% | |
| EPS Growth (YoY) | +25.2% | -184.2% | -47.6% | -9.7% | -38.2% | +27.7% | +29.4% | +16.7% | -15.0% | |
| Shares Change (YoY) | -20.9% | -4.3% | -2.4% | +1.7% | +1.3% | +1.9% | +1.5% | +1.8% | +11.3% | |
| FCF Growth (YoY) | +56.8% | -69.1% | -31.2% | -13.7% | -71.5% | +28.3% | +16.8% | +40.9% | -43.5% | |
| Gross Margin | 12.9% | 10.3% | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | -88.3% |
| Operating Margin | -1004.5% | -939.7% | -586.1% | -552.2% | -625.9% | -612.7% | -346.9% | -283.9% | -168.8% | -579.9% |
| EBITDA Margin | 0.0% | -290.4% | -582.9% | 0.0% | -622.0% | -463.4% | -345.2% | -281.3% | -154.0% | -560.6% |
| Net Margin | -608.7% | -281.6% | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% |
| FCF Margin | -1018.0% | -343.6% | -340.2% | -344.0% | -410.4% | -469.1% | -275.9% | -232.1% | -113.7% | -462.7% |
| Effective Tax Rate | -7.1% | 3.0% | 15.0% | -0.1% | -0.3% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-0.17 | $-0.09 | $-0.16 | $-0.21 | $-0.24 | $-0.41 | $-0.28 | $-0.23 | $-0.14 | $-0.17 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $36.5M | $28.9M | $27.7M | $27.0M | $27.5M | $27.8M | $28.4M | $28.8M | $29.3M | $32.6M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -2918.10% |
| Return on Invested Capital | -278.95% |
| Return on Assets | -116.60% |
| Gross Margin | 30.44% |
| Operating Margin | -213.59% |
| Net Margin | -219.50% |
Financial Health
| Debt / Equity | -2.11 |
| Current Ratio | 1.65 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -16.80 | -18.94 | -9.00 | -16.71 | -15.82 | -9.62 | -3.62 | -6.71 | -8.75 | -4.09 |
| P/B | 1.05 | 0.81 | 1.23 | 3.90 | 5.20 | 6.84 | 3.15 | 7.89 | 20.77 | 24.88 |
| P/S | 102.30 | 53.38 | 40.37 | 83.21 | 92.26 | 52.34 | 11.91 | 15.99 | 14.68 | 24.89 |
| Gross Margin | 12.9% | 10.3% | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | -88.3% |
| Operating Margin | -1004.5% | -939.7% | -586.1% | -552.2% | -625.9% | -612.7% | -346.9% | -283.9% | -168.8% | -579.9% |
| Net Margin | -608.7% | -281.6% | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks